Good morning. Elizabeth Cooney here, filling in for Ed Silverman this week as he makes those daydreams of vacation plans come true. Here’s what we’re watching today from Boston HQ:

Guardant Health has published results saying its blood test could replace biopsy for rare cancer treated by Keytruda, STAT reports. Currently, identifying such cancers, called MSI-High, for “microsatellite instable-high,” requires examining a tumor that had been surgically removed. Merck’s (MRK) Keytruda is approved to treat tumors that appear anywhere in the body, but are marked with a specific genetic signature.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Elizabeth, thank you for filling in for Ed Silverman, and with a BIG “Little.”
    I was struck by the fact that you included a fact many omit in your Immuneel item. It was – “That cost, which includes hospital and medical expenses, ” – which costs are also included in the … “very high” prices quoted for the “list price” on those therapies in the US.
    The pricing is an “all in” that includes much more than just ‘the drug,’ but always seems to get passed over in the discussion / screed about pricing. These are not just a pill and need to be supplied in a large and ostly ecosystem. Factors that get scant attention.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy